File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Article: Adiponectin as a key player of inflammation

TitleAdiponectin as a key player of inflammation
Authors
KeywordsAdipokine
Adipopharmacology
Atherosclerosis
Diabetes
Obesity
Issue Date2006
PublisherBulgarian Society for Cell Biology. The Journal's web site is located at http://www.bgscb.org/articles/bmr
Citation
Biomedical Reviews, 2006, v. 17, p. 11-22 How to Cite?
AbstractChronic inflammation has recently been proposed to be a key mediator linking obesity to a cluster of cardiometabolic disorders. Obese adipose tissue, infiltrated with activated macrophages and mast cells, is an important source of systemic inflammation, by secreting dozens of the pro-inflammatory adipokines into the blood stream. One the other hand, adiponectin, an abundant adipokine secreted predominantly from adipocytes, is markedly decreased in obesity and associated inflammatory diseases. Adiponectin exerts its anti-inflammatory actions in several target cells by inhibiting the production and activities of tumor necrosis factor-alpha, preventing the activation of nuclear factor-kappa B, and inducing expression of anti-inflammatory cytokines. In animal models, adiponectin treatment alleviates several obesity-associated inflammatory diseases, such as atherosclerosis, nonalcoholic steatohepatitis, asthma and acute myocardial infarction. In humans, circulating levels of adiponectin are inversely correlated with several well-established markers of inflammation, including C-reactive protein and interleukin-6. Furthermore, anti-inflammatory drugs, such as peroxisome proliferator-activated receptor-gamma agonists, can elevate plasma levels of adiponectin. While the majority of clinical and animal data support the role of adiponectin as an anti-inflammatory, anti-atheroscerotic and anti-diabetic adipokine, a number of recent studies have reported its pro-inflammatory actions in certain conditions. Here, we summarize the pathophysiological roles of adiponectin in inflammation-related disorders, and discuss the potential mechanisms involved, also their implications in adiponectin-targeted pharmacotherapy.
Persistent Identifierhttp://hdl.handle.net/10722/76697
ISSN
2015 SCImago Journal Rankings: 0.166

 

DC FieldValueLanguage
dc.contributor.authorCheng, KKYen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorXu, Aen_HK
dc.date.accessioned2010-09-06T07:23:58Z-
dc.date.available2010-09-06T07:23:58Z-
dc.date.issued2006en_HK
dc.identifier.citationBiomedical Reviews, 2006, v. 17, p. 11-22en_HK
dc.identifier.issn1310-392Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/76697-
dc.description.abstractChronic inflammation has recently been proposed to be a key mediator linking obesity to a cluster of cardiometabolic disorders. Obese adipose tissue, infiltrated with activated macrophages and mast cells, is an important source of systemic inflammation, by secreting dozens of the pro-inflammatory adipokines into the blood stream. One the other hand, adiponectin, an abundant adipokine secreted predominantly from adipocytes, is markedly decreased in obesity and associated inflammatory diseases. Adiponectin exerts its anti-inflammatory actions in several target cells by inhibiting the production and activities of tumor necrosis factor-alpha, preventing the activation of nuclear factor-kappa B, and inducing expression of anti-inflammatory cytokines. In animal models, adiponectin treatment alleviates several obesity-associated inflammatory diseases, such as atherosclerosis, nonalcoholic steatohepatitis, asthma and acute myocardial infarction. In humans, circulating levels of adiponectin are inversely correlated with several well-established markers of inflammation, including C-reactive protein and interleukin-6. Furthermore, anti-inflammatory drugs, such as peroxisome proliferator-activated receptor-gamma agonists, can elevate plasma levels of adiponectin. While the majority of clinical and animal data support the role of adiponectin as an anti-inflammatory, anti-atheroscerotic and anti-diabetic adipokine, a number of recent studies have reported its pro-inflammatory actions in certain conditions. Here, we summarize the pathophysiological roles of adiponectin in inflammation-related disorders, and discuss the potential mechanisms involved, also their implications in adiponectin-targeted pharmacotherapy.-
dc.languageengen_HK
dc.publisherBulgarian Society for Cell Biology. The Journal's web site is located at http://www.bgscb.org/articles/bmren_HK
dc.relation.ispartofBiomedical Reviewsen_HK
dc.subjectAdipokine-
dc.subjectAdipopharmacology-
dc.subjectAtherosclerosis-
dc.subjectDiabetes-
dc.subjectObesity-
dc.titleAdiponectin as a key player of inflammationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1310-392X&volume=17&spage=11&epage=22&date=2006&atitle=Adiponectin+as+a+key+player+of+inflammationen_HK
dc.identifier.emailCheng, KKY: bc_ckyab@hotmail.comen_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailWang, Y: yuwanghk@hkucc.hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.authorityCheng, KKY=rp01672en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityWang, Y=rp00239en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.hkuros129070en_HK
dc.identifier.volume17-
dc.identifier.spage11-
dc.identifier.epage22-
dc.publisher.placeBulgaria-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats